Tada,

"If I had to guess I would say that if the company knew when they were designing BETonMACE what they know today that this would have been a CKD or a cognitive function trial and not a CVD trial. Both of those markets are bigger with less competition."

This is only a (MoCA) "Cognitive Evaluation of Treatment Effects of the Bromodomain Inhibitor Apabetalone" This alone provides an indication for dementia. It does not cure it. But it does bring it to light or prolong it.

Concerning CKD, we need to let this play out...https://clinicaltrials.gov/ct2/show/NCT03160430

Just saying....Koo